NCT04043975View on ClinicalTrials.gov

A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan

CompletedOBSERVATIONAL
Enrollment

286

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

August 23, 2024

Study Completion Date

August 23, 2024

Conditions
Advanced or Metastatic Renal Cell Carcinoma
Trial Locations (1)

1070052

Local Institution - 0001, Tokyo

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT04043975 - A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan | Biotech Hunter | Biotech Hunter